Neogenomics Inc (NEO) · Oct 5, 2026 · Earnings
Beat — Preliminary revenue $209M vs ~$205.8M consensus
NeoGenomics’ preliminary third-quarter earnings point to a modest revenue beat and another full-year guidance increase, alongside a planned CEO transition.
NeoGenomics is expanding oncology diagnostics through higher-growth NGS testing, community-oncology adoption, and newer therapy-selection and molecular-residual-disease offerings. Its 2026 plan centers on targeted product launches, MRD investment, and broader use of precision testing in community care.
The preliminary quarter is modestly ahead of expectations. Revenue of approximately $209 million is about $3.2 million, or 1.6%, above the published consensus of roughly $205.8 million. The filing also points to particularly strong momentum in NGS, with growth of approximately 28% year over year.
| Metric | Filing / expectation | Comparison |
|---|---|---|
| Preliminary Q3 2026 revenue | Approximately $209M | Consensus approximately $205.8M |
| NGS revenue growth | Approximately 28% YoY | No consensus comparison provided |
| FY 2026 revenue guidance | Expected to increase from the prior $802M–$806M range | Prior midpoint $804M |
| FY 2026 adjusted EBITDA guidance | Reiterated | No change disclosed |
The more important signal is the pending revenue-guidance increase. Management is reiterating adjusted EBITDA guidance while saying full-year revenue guidance should rise because of third-quarter performance. 〔0〕 〔1〕 That suggests the upside is currently showing up more clearly in demand and volume than in a broader profitability reset; the exact new range is not yet disclosed.
The CEO change is designed to preserve continuity, not redirect the business. President and COO Warren Stone will become CEO on January 4, 2027, while current CEO Tony Zook becomes Executive Chair and Lynn Tetrault exits the chair role after the 2027 annual meeting. Because Stone has already led clinical services, commercial operations, and the broader operating organization, the filing presents this as an internal succession plan rather than a strategic reset. The change is still a new execution variable, but there is no disclosed disruption or change to the current growth priorities.
Bottom line: This is a small but real operating positive: revenue is tracking above consensus and management expects to lift the full-year revenue outlook again. The leadership transition matters, but its planned internal nature limits the immediate change to the business story.
Q3 earnings call, late October
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.